MD3512543T2 - Mutații de stabilizare a trimerului proteinei de înveliș HIV - Google Patents

Mutații de stabilizare a trimerului proteinei de înveliș HIV

Info

Publication number
MD3512543T2
MD3512543T2 MDE20190798T MDE20190798T MD3512543T2 MD 3512543 T2 MD3512543 T2 MD 3512543T2 MD E20190798 T MDE20190798 T MD E20190798T MD E20190798 T MDE20190798 T MD E20190798T MD 3512543 T2 MD3512543 T2 MD 3512543T2
Authority
MD
Moldova
Prior art keywords
hiv
hiv envelope
envelope protein
proteins
envelope proteins
Prior art date
Application number
MDE20190798T
Other languages
English (en)
Inventor
Lucy Rutten
Daphne Truan
Nika Mindy Strokappe
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MD3512543T2 publication Critical patent/MD3512543T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Proteine de înveliş ale virusului imunodeficienţei umane (HIV) având mutaţii care stabilizează forma trimerică a proteinei de înveliş. Proteinele de înveliş HIV au anumite substituţii de aminoacizi în poziţii specificate în secvenţa de proteină de înveliş. Proteinele de înveliş HIV descrise au un procent îmbunătăţit de trimer şi/sau un randament îmbunătăţit al trimerului în comparaţie cu o proteină de înveliş HIV care nu are una sau mai multe dintre substituţiile de aminoacizi indicate. De asemenea, sunt furnuzate molecule de acid nucleic şi vectori care codifică proteinele de înveliş HIV, precum şi compoziţii care conţin proteine de înveliş HIV, acid nucleic şi vectori.
MDE20190798T 2016-09-15 2017-09-14 Mutații de stabilizare a trimerului proteinei de înveliș HIV MD3512543T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188866 2016-09-15
PCT/EP2017/073141 WO2018050747A1 (en) 2016-09-15 2017-09-14 Trimer stabilizing hiv envelope protein mutations

Publications (1)

Publication Number Publication Date
MD3512543T2 true MD3512543T2 (ro) 2020-11-30

Family

ID=57017955

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190798T MD3512543T2 (ro) 2016-09-15 2017-09-14 Mutații de stabilizare a trimerului proteinei de înveliș HIV

Country Status (30)

Country Link
US (3) US10793607B2 (ro)
EP (2) EP3512543B1 (ro)
JP (2) JP7178344B2 (ro)
KR (1) KR102513146B1 (ro)
CN (1) CN109689091A (ro)
AR (1) AR109528A1 (ro)
AU (2) AU2017327672B2 (ro)
BR (1) BR112019004593A2 (ro)
CA (1) CA3036959A1 (ro)
CY (1) CY1124518T1 (ro)
DK (1) DK3512543T3 (ro)
EA (1) EA201990715A1 (ro)
ES (1) ES2824525T3 (ro)
HR (1) HRP20201458T1 (ro)
HU (1) HUE052008T2 (ro)
IL (2) IL265186B (ro)
LT (1) LT3512543T (ro)
MA (1) MA46230B1 (ro)
MD (1) MD3512543T2 (ro)
MX (1) MX2019002938A (ro)
MY (1) MY190534A (ro)
PH (1) PH12019500280A1 (ro)
PL (1) PL3512543T3 (ro)
PT (1) PT3512543T (ro)
RS (1) RS60919B1 (ro)
SG (2) SG10202001956UA (ro)
SI (1) SI3512543T1 (ro)
TW (1) TWI742158B (ro)
WO (1) WO2018050747A1 (ro)
ZA (1) ZA201901597B (ro)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3390430B1 (en) 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2017192434A1 (en) * 2016-05-02 2017-11-09 The Scripps Research Institute Compositions and methods related to hiv-1 immunogens
CN109219448B (zh) 2016-06-16 2022-09-20 扬森疫苗与预防公司 Hiv疫苗配制品
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) * 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US11161895B2 (en) 2016-10-03 2021-11-02 Duke University Methods to identify immunogens by targeting improbable mutations
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
SG11202012313PA (en) 2018-06-13 2021-01-28 Scripps Research Inst Nanoparticle vaccines with novel structural components
EA038287B1 (ru) * 2018-06-18 2021-08-04 Янссен Вэксинс Энд Превеншн Б.В. Стабилизирующие тример мутации белка оболочки hiv
CA3114870A1 (en) * 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
JP2022523044A (ja) * 2019-01-22 2022-04-21 ブルーバード バイオ， インコーポレイテッド ウイルスベクターを製造するための方法及びシステム
CN110184298B (zh) * 2019-05-15 2023-05-16 武汉璟泓科技股份有限公司 Hiv突变型表面糖蛋白及其纳米化抗原与制备方法
WO2021097254A1 (en) * 2019-11-14 2021-05-20 Emory University Hiv immunogens, vaccines, and methods related thereto
US20240000919A1 (en) * 2020-11-12 2024-01-04 Xiamen University Modified envelope protein of human immunodeficiency virus and use thereof
WO2022180007A1 (en) 2021-02-23 2022-09-01 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2023192835A1 (en) * 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
IL154712A0 (en) 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
US20070166784A1 (en) 2003-09-15 2007-07-19 Barnett Susan W Combination approaches for generating immune responses
EP2371387A3 (en) * 2003-09-17 2012-01-25 Duke University HIV consensus sequence antigens and their use in vaccina
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
CA2573702C (en) 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
CN1857345B (zh) * 2005-05-08 2010-09-01 谢秀琼 一种治疗偏头痛的药物组合物及其制备方法
WO2007005934A2 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CA2655934A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
MX362698B (es) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
SI2340038T1 (en) 2008-10-10 2018-05-31 Children's Medical Center Corporation A biochemically stabilized HIV-1 ENV TRIMER vaccine
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
EP2529010B1 (en) 2010-01-28 2017-04-19 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
EA030983B1 (ru) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
CN112121160A (zh) 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
EP3390430B1 (en) 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CN109219448B (zh) 2016-06-16 2022-09-20 扬森疫苗与预防公司 Hiv疫苗配制品
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
AU2018304502B2 (en) * 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations

Also Published As

Publication number Publication date
ES2824525T3 (es) 2021-05-12
US11365222B2 (en) 2022-06-21
AU2017327672B2 (en) 2020-10-15
AU2017327672A1 (en) 2019-02-28
LT3512543T (lt) 2020-11-10
WO2018050747A1 (en) 2018-03-22
KR20190050786A (ko) 2019-05-13
BR112019004593A2 (pt) 2019-07-02
TWI742158B (zh) 2021-10-11
KR102513146B1 (ko) 2023-03-23
PT3512543T (pt) 2020-10-13
SG11201901206SA (en) 2019-04-29
PL3512543T3 (pl) 2021-01-11
AU2020267278B2 (en) 2023-07-20
RS60919B1 (sr) 2020-11-30
CN109689091A (zh) 2019-04-26
AR109528A1 (es) 2018-12-19
MY190534A (en) 2022-04-27
IL265186B (en) 2022-09-01
IL294832A (en) 2022-09-01
MX2019002938A (es) 2019-10-15
DK3512543T3 (da) 2020-10-12
CY1124518T1 (el) 2022-03-24
CA3036959A1 (en) 2018-03-22
TW201819401A (zh) 2018-06-01
HRP20201458T1 (hr) 2020-12-11
SI3512543T1 (sl) 2020-10-30
SG10202001956UA (en) 2020-04-29
PH12019500280A1 (en) 2019-10-28
EA201990715A1 (ru) 2019-08-30
IL265186A (en) 2019-05-30
NZ750773A (en) 2021-02-26
ZA201901597B (en) 2022-12-21
JP2023011941A (ja) 2023-01-24
JP7178344B2 (ja) 2022-11-25
US10793607B2 (en) 2020-10-06
EP3512543B1 (en) 2020-07-22
MA46230B1 (fr) 2020-10-28
US20200369731A1 (en) 2020-11-26
US11820796B2 (en) 2023-11-21
EP3512543A1 (en) 2019-07-24
US20180072777A1 (en) 2018-03-15
US20220315627A1 (en) 2022-10-06
JP2019534690A (ja) 2019-12-05
AU2020267278A1 (en) 2020-12-10
MA46230A (fr) 2019-07-24
EP3747463A1 (en) 2020-12-09
HUE052008T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
MD3512543T2 (ro) Mutații de stabilizare a trimerului proteinei de înveliș HIV
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2018014228A (es) Proteina de union de albumina sérica de dominio unico.
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2021003475A (es) Metodos de purificacion de proteinas.
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2018002825A1 (es) Vacuna contra vrs
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
EA201991607A1 (ru) Генетически модифицированные клетки-натуральные киллеры
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
BR112022000545A2 (pt) Composições de proteína e produtos de consumo destas
EA201991918A1 (ru) Самосборные белковые наночастицы со встроенными белками с шестиспиральным пучком
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
WO2019014260A3 (en) BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
UY36616A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита